Navigation Links
Ossur -- leading orthopedic pioneer - expands network to Asia
Date:10/5/2007

October 5, 2007 - Shanghai Ossur, a leading provider of non-invasive orthopaedic products and services, today announced the inauguration of its Asia Pacific operations in Shanghai, China. Ossur, renowned for its pioneering work in lower-limb prosthetics and a comprehensive range of braces and supports, established its China office as the regional headquarters catering to customers not just in China but across Asia including Japan, South Korea and Australia.

The total prosthetic market in Asia is USD260 million of which USD56 million is in components and devices. In China, we estimate the total market being USD35 million. In Asia, lifestyle diseases such as diabetes and other arterial diseases that lead to amputation are showing a significant rise as compared to Western countries. In addition, workplace accidents or trauma have also led to increased lower-limb amputations. There are approximately 2.2 million amputees in China with over 100,000 new amputees expected each year . It is estimated that 70% of amputations are related to some form of trauma .

China will become the third largest healthcare market by the year 2020, said Arni Alvar Arason, president Ossur Asia. China has all the key elements that make it the ideal choice for our regional headquarters investment, distribution, supply chain network, proximity to key Asian markets - not to mention a growing patient base requiring prosthetics. Ossur is already looking into setting up manufacturing and R&D capabilities in the very near future. Currently, Ossur provides prosthetics and components to about 15,000 Chinese patients who use them on a daily basis. When Ossur begins to supply and distribute braces and supports from its Asia office, this category is expected to grow significantly.

Establishing an office in China to meet market demand in this region is part of Ossurs 2010 company vision: to focus more on Asian markets. Presiding at the inauguration, president & CEO Jon Sigurdsson stressed the importance of building Ossur in key growth areas. What inspires Ossurs growth is recognizing the needs of our customers and meeting them, whether it is in products, technology, education or in the supply chain. We see China as an important growth market for us.

Ossur launched a new Bionic Technology platform of products in 2005, transitioning the company towards sophisticated high-end electronics and software development. Microprocessors and the development of critical electronic parts are becoming an increasingly important part of the prosthetic development phase. The proximity to a strong patient population as well as an electronics industry in Asia, not to mention the growing orthopaedic and prosthetic medical community in Shanghai, makes China a good location.

Ossur is not only about products. Ossur provides extensive educational and clinical support programs through the Ossur Academy, a global initiative to assist orthopaedic professionals and prosthetists in delivering the best possible experience and outcome for their patients. Ossur currently sponsors university level courses to several universities in the region. Based on growing patient demand, the Orthopaedic and Prosthetic industry will greatly benefit from Ossurs education and technical support programs in China and Asia while, at the same time, helping to develop the O&P industry in the region.

Prosthetics in Japan, South Korea and Australia are expected to be core growth areas over the next 2-3 years. In China, the bracing and support market will continue to be developed through its network of local partners and distributors in the region. Arason added, our philosophy is to continue to enhance and develop quality solutions and to be the leader in this field. Ossur is not about fitting legs. Ossur is about making a difference and bringing people back to the same standard of living that they enjoyed before. For our patients, we believe in a life without limitations. That is our commitment.


'/>"/>

Contact: Edda Geirsdottir
egeirsdottir@ossur.com
354-664-1055
Ossur
Source:Eurekalert

Related biology news :

1. Enzyme allows B cells to resist death, leading to leukemia
2. Scientists document complex genomic events leading to the birth of new genes
3. Genetic links could unlock clues to leading cause of blindness
4. Leading scientists rank endangered dolphins, porpoises most in need of immediate action
5. Why do aneurysms form? New studies suggest leading role for white blood cells
6. Leading lampreys to slaughter: Pheromone for scourge of Great Lakes identified
7. Jefferson scientists identify gene defect leading to abnormal skin development and cancer
8. ORNL leading effort to help harness power of Shewanella
9. Leading reason for corneal transplants comes into focus
10. Twin studies reveal genetic components leading to cardiac and kidney disease
11. Climate change could trigger boom and bust population cycles leading to extinction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology: